



**Maryland Prescription Drug Affordability Board**  
**Meeting Agenda**

July 22, 2024 — 2:00 p.m.  
(Amended July 17, 2024)

- I. Call Meeting to Order
- II. Approve May 20, 2024 Meeting Minutes
- III. Opportunity for Public Comment<sup>1</sup>
- IV. Cost Review
  - a. Amend Prior Board Action to Approve Individual Drugs For Cost Review Study Process
  - b. Amend Prior Board Action to Approve Skyrizi and Dupixent For Cost Review Study Process Following Study of Diabetes Drugs
  - c. Amend Prior Board Action to Approve Therapeutic Alternatives and Specified List of Insulins
  - d. Cost Review Study Process Update-Presentation
- V. Regulations
  - a. Approve Final Regulations COMAR 14.01.02 (Prescription Drug Affordability Fund)
- VI. UPL Action Plan Update
- VII. Annual Report- Policies and Options
- VIII. Administrative Update
  - a. FY24 Fee Assessment
  - b. FY24 Closeout
- IX. Chair's Update
- X. Adjournment

---

<sup>1</sup> The public may submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [comments.pdab@maryland.gov](mailto:comments.pdab@maryland.gov). For more information on presenting comments during the meeting, please visit the Board Meetings page at the PDAB's website.

This meeting will be live-streamed [here](#), therefore registration is not required. You may also attend in person at the [Miller Senate Building](#), William Amoss Room, 4th Floor, Annapolis, MD. Please visit the PDAB website to learn more about how to submit written comments and sign up for oral public comment.

Next PDAB Meeting: The Board's next regularly scheduled meeting will be on September 23, 2024. Registration information for this meeting will be published on the PDAB website at [pdab.maryland.gov](http://pdab.maryland.gov).